Mankind Pharma sets IPO price band of Rs 1,026 to Rs 1,080 per share

Published On 2023-04-19 08:00 GMT   |   Update On 2023-04-19 08:00 GMT
Advertisement

Bengaluru: Indian pharmaceutical company Mankind Pharma Ltd has set a price band of 1,026 rupees to 1,080 rupees per share for its initial public offering (IPO), according to a newspaper advertisement, valuing the company at 432.64 billion rupees ($5.27 billion) at the upper end of the band.

The IPO for the company, which owns the Manforce condom brand and pregnancy testing kit Prega News, will consist of nearly 40.1 million shares on offer for sale from existing shareholders, according to a draft prospectus, with an offer size of 43.26 billion rupees.

Advertisement

Read also: Mankind Pharma acquires majority stake in Upakarma Ayurveda

The company’s profit for the nine months ended Dec. 31 fell to 9.96 billion rupees from 12.43 billion rupees a year ago, while its revenue from operations for the same period rose nearly 11%.

Mankind had filed draft papers for the IPO in September last year, with Kotak Mahindra Capital, Axis Capital and J.P. Morgan India among the book running lead managers




Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News